Chris Evans (WA, Australian Labor Party, Leader of the Government in the Senate) Share this | Hansard source

The answer to the honourable senator's question is as follows:

(1) As noted in response to Senate Estimates question SI-155 (Supplementary Budget Estimates Hearing, 19 October 2011), there have been informal partnership discussions on this topic. There have been no recent discussions on the matter.

(2) Yes.

(3) Yes.

(4) This question should be directed to the parties to the commercial venture.

(5) This question should be directed to the parties to the commercial venture.

(6) Please see answer to Senate Estimates question SI-155.

(7) This question should be directed to the University of Queensland.

(8) This question should be directed to the Centre for Advanced Imaging.

(9) As noted in response to Senate Estimates question SI-155, ANSTO has contributed funding as part of a collaboration with Austin Health/Ludwig Institute for Cancer Research for a competitive research cyclotron access for novel radioisotopes on an open proposal basis to the Australian research community. This covered the cost of hot cells, targetry and radiochemical equipment. The cyclotron was already funded and established by Austin Health/Ludwig, meaning that ANSTO's funding leveraged this underlying investment. In addition, ANSTO receives a weekly delivery of one of four radioisotopes (for research purposes) and training in solid targetry which would not otherwise be available to ANSTO staff.

(a) June 2010 and February 2012.

(b) Neither.

(c) No.

(10) Yes. Cu-64 and I-124 have been supplied to date.

(11) Please see answer to Senate Estimates Question SI-155

(12) The University of Queensland, the Peter MacCallum Cancer Centre and ANSTO have received Cu-64 and Zr-89.

(13) ANSTO cannot answer this answer this question on behalf of Sir Charles Gairdner Hospital or the Ludwig Institute.

(14) (a) ANSTO is unaware whether Cyclopharm can successfully produce Cu-64, (b) Yes.

(15) No.

(16) ANSTO is not aware of any such formal proposal being made.

(17) As noted in response to Senate Estimates question SI-155, as required by section 27F of the Commonwealth Authorities and Companies Act 1997, ANSTO requires any director who has a material personal interest in a matter that relates to ANSTO's affairs to give the other directors notice of the interest. To that end, ANSTO maintains a Board register of interests, which is updated at each Board meeting.